Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
01 2Shanghai Minbiotech
02 1AR Life Sciences
03 1Actis Generics Pvt Ltd
04 1Almelo
05 1Amara Labs
06 1Ami Organics Private Limited
07 1Aptra Synthesis
08 1Chemeca Drugs
09 1Corey Organics
10 1Cubane Pharmaceuticals
11 1Dalian Richon Chem
12 1Elixir Pharma
13 1Epoch Labs
14 1Glenfin Chemicals
15 1Indian Tex Dyes Industries
16 1Jinan Lead Pharmaceutical Technology
17 1Loxim Industries
18 1Rampex Labs
19 1Royal Pharma
20 1SS Pharma
21 1Sigmak Lifesciences
22 1Smilax Laboratories Limited
23 1Srini Pharmaceuticals
24 1Synaptic Labs
25 1Trichem Life Sciences Ltd
26 1Venkata Narayana Active Ingredients
27 1Vijayasri Organics Limited
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. Th...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. Th...
N-(4-Cyanophenyl)glycine(or) 2-(4-Cyanophenylamino...
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Actis Generics Pvt Ltd is a fast emerging APIs (Active Pharmaceutical Ingredients) & Intermediates manufacturer & supplier in India set up by a group of young professionals with the spe...
CAS Number : CAS-42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse product portfolio coupled ...
2-[(4-CYANOPHENYL)AMINO]ACEITIC ACID
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Amara Labs Pvt Ltd is a WHO-GMP certified manufacturing company wholly owned by a team of technocrats with working experience of more than 20 years in Multi-Nationals Companies like Myl...
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. is committed to meeting yo...
2-(4-Cyano phenyl amino) acetic acid
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to GMP st...
2-(4-Cyanophenylamino) Acetic Acid
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : We are into manufacturing of bulk drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is contract manufacturing for our clients who are looking for manuf...
2-(4-Cyanophenyl)aminoaceticacid
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its Manufacturing Facility U...
CAS Number : 42288-26-6
End Use API :
End Use API : Dabigatran Etexilate Mesylate
About the Company : Corey Organics is focused in developing and manufacturing of Active Pharmaceutical Ingredients (APIs), registered Pharma Intermediates, Fine Chemicals and Pyridine Derivatives for cater...
